TABLE 4.
Maintenance rate of target Hb level (full analysis set)
| ESA‐Naïve StudyaWeeks 18‐24 | ESA‐Converted Studyb All ESA‐Converted | ||||
|---|---|---|---|---|---|
| Roxadustat 50 mg | Roxadustat 70 mg | All ESA‐Naïve | N = 163 | ||
| Parameter | N = 37 | N = 37 | N = 74 | Weeks 18‐24 | Weeks 46‐52 |
| All patients | |||||
| Maintenance rate, n (%) | 28/37 (75.7) | 26/37 (70.3) | 54/74 (73.0) | 129/163 (79.1) | 116/163 (71.2) |
| 95% CI, % | 58.8, 88.2 | 53.0, 84.1 | 61.4, 82.6 | 72.1, 85.1 | 63.6, 78.0 |
| Patients with at least one Hb value | |||||
| Maintenance rate, n (%) | 28/33 (84.8) | 26/32 (81.3) | 54/65 (83.1) | 129/148 (87.2) | 116/128 (90.6) |
| 95% CI, % | 68.1, 94.9 | 63.6, 92.8 | 71.7, 91.2 | 80.7, 92.1 | 84.2, 95.1 |
Note: Target Hb level, mean Hb 10.0 to 12.0 g/dL.
Abbreviations: CI, confidence interval; ESA, erythropoiesis‐stimulating agent; Hb, hemoglobin.
a
The study duration was 24 weeks.
b
The study duration was 52 weeks.